Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2026)
Recursion Pharmaceuticals' (RXRX) quarterly Operating Leases came in at $42.8 million in Q1 2026, down 23.53% YoY from $56.0 million in Q1 2025, and down 8.16% on a QoQ basis from $46.6 million in Q4 2025.
Recursion Pharmaceuticals (RXRX) Operating Leases (2022 - 2026) Analysis & Trends
Recursion Pharmaceuticals (RXRX) has 5 years of Operating Leases data on file, last reported at $42.8 million in Q1 2026.
- Quarterly Operating Leases fell 23.53% year-over-year to $42.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $42.8 million (down 23.53% YoY) and the FY2025 annual result came in at $46.6 million, down 30.64% from the prior year.
- Operating Leases eased to $42.8 million in Q1 2026, from $46.6 million in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $88.8 million in Q2 2024 to a low of $42.8 million in Q1 2026.
- A 5-year average of $52.5 million and a median of $50.0 million in 2025 frame the typical range for Operating Leases.
- Annual changes were most pronounced in 2024 — Operating Leases soared 73.82% — and 2025, when it sank 39.85%.
- Tracing RXRX's Operating Leases over 5 years: stood at $44.4 million in 2022, then fell by 2.26% to $43.4 million in 2023, then soared by 54.9% to $67.2 million in 2024, then sank by 30.64% to $46.6 million in 2025, then retreated by 8.16% to $42.8 million in 2026.
- The last three Operating Leases figures came in at $42.8 million (Q1 2026), $46.6 million (Q4 2025), and $50.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Recursion Pharmaceuticals | 1.69 Bn | 1.14 Bn | -3.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.19 Mn |
| Mar 31, 2026 | 42.84 Mn |
| Dec 31, 2025 | 46.65 Mn |
| Sep 30, 2025 | 50.03 Mn |
| Jun 30, 2025 | 53.40 Mn |
| Mar 31, 2025 | 56.02 Mn |
| Dec 31, 2024 | 67.25 Mn |
| Sep 30, 2024 | 61.90 Mn |
| Jun 30, 2024 | 88.77 Mn |
| Mar 31, 2024 | 43.79 Mn |
| Dec 31, 2023 | 43.41 Mn |
| Sep 30, 2023 | 44.30 Mn |
| Jun 30, 2023 | 51.07 Mn |
| Mar 31, 2023 | 46.77 Mn |
| Dec 31, 2022 | 44.42 Mn |
| Sep 30, 2022 | 51.53 Mn |
| Jun 30, 2022 | 53.01 Mn |
| Mar 31, 2022 | 47.32 Mn |